The Supervisory Board of Lek appointed new Board of Management

27. 9. 2019

At its meeting in late September, the Supervisory Board of Lek appointed a new Board of Management on the proposal of Robert Ljoljo, President of the Board of Management of Lek and Novartis Country President Slovenia who assumed the new role on September 1 this year. 

The Board of Management of Lek d.d. will from October 1, 2019 consist of: Ivan Ďurovčík, Head Finance, Ksenija Butenko Černe, Head Legal, Prof. Uroš Urleb, PhD, Global Head Technical Development Biosimilars at Novartis and Site Head Biologics Technical Development Mengeš, Raul Intriago Lombeida, Global Head Novartis Operations Centers for Novartis Technical Operations, Andrej Pardo, Cluster Head Region Europe at Sandoz, and Marjan Novak, Worker’s Director.

Ivan Ďurovčík is a Member of the Board of Management of Lek for Finance and Novartis Business Services (résumé).

Ksenija Butenko Černe is a Member of the Board of Management of Lek for Legal and Compliance (résumé).

Prof. Uroš Urleb, PhD, is a Member of the Board of Management of Lek for Research and Development (résumé).

Raul Intriago Lombeida is a Member of the Board of Management of Lek for Novartis Technical Operations (résumé).

Andrej Pardo is a Member of the Board of Management of Lek for Commercial Operations. (résumé)

Marjan Novak is Worker’s Director and a Member of the Board of Management of Lek (résumé)

The Board of Management has been appointed for a period of five years. 

* * *

Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last seven years, the company has created more than 2,250 jobs, making us one of the biggest employers in Slovenia. Novartis invested in Slovenia more than EUR 2.3 billion since 2003. 

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars and a pioneer in the emerging field of prescription digital therapeutics. Our purpose is to pioneer access to healthcare by developing and commercializing novel, affordable approaches that address unmet medical need. Our broad portfolio of high-quality medicines, covering all major therapeutic areas and increasingly focused on value-adding differentiated medicines, accounted for 2018 sales of USD 9.9 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Sandoz is on Twitter. Sign up to follow @SandozGlobal at

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108 thousand people of more than 140 nationalities work at Novartis around the world. Find out more at 

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32